REFERENCES
1. Roden DM, McLeod HL, Relling MV, Williams MS, Mensah GA, et al. Pharmacogenomics. Lancet 2019;394:521-32.
2. Mini E, Nobili S. Pharmacogenetics: implementing personalized medicine. Clin Cases Miner Bone Metab 2009;6:17-24.
3. Wake DT, Ilbawi N, Dunnenberger HM, Hulick PJ. Pharmacogenomics: prescribing precisely. Med Clin North Am 2019;103:977-90.
4. Levitzki A, Klein S. My journey from tyrosine phosphorylation inhibitors to targeted immune therapy as strategies to combat cancer. Proc Natl Acad Sci U S A 2019;116:11579-86.
5. Church D, Kerr R, Domingo E, Rosmarin D, Palles C, et al. ‘Toxgnostics’: an unmet need in cancer medicine. Nat Rev Cancer 2014;14:440-5.
6. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013;13:714-26.
7. FDA. List of cleared or approved companion diagnostic devices (in vitro and imaging tools). Available from: https://www.fda.gov/media/119249/download [Last accessed on 12 Feb 2020].
8. EMA. Concept paper on predictive biomarker-based assay development in the context of drug development and lifecycle. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-predictive-biomarker-based-assay-development-context-drug-development-lifecycle_en.pdf [Last accessed on 12 Feb 2020].
9. PharmGKB website. Available from: https://www.pharmgkb.org [Last accessed on 12 Feb 2020].
11. Olivera G, Sendra L, José Herrero M, Berlanga P, Gargallo P, et al. Pharmacogenetics implementation in the clinics: information and guidelines for germline variants. Cancer Drug Resist 2019;2:53-68.
12. Crisafulli C, Romeo PD, Calabrò M, Epasto LM, Alberti S. Pharmacogenetic and pharmacogenomic discovery strategies. Cancer Drug Resist 2019;2:225-41.
13. Tarantino P, Trapani D, Morganti S, Ferraro E, Viale G, et al. Opportunities and challenges of implementing pharmacogenomics in cancer drug development. Cancer Drug Resist 2019;2:43-52.
14. Hierro C, Matos I, Martin-Liberal J, Ochoa de Olza M, Garralda E. Agnostic-histology approval of new drugs in oncology: are we already there? Clin Cancer Res 2019;25:3210-19.
15. Renfro LA, An MW, Mandrekar SJ. Precision oncology: a new era of cancer clinical trials. Cancer Lett 2017;387:121-6.
16. Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, et al. Comprehensive characterization of cancer driver genes and mutations. Cell 2018;173:371-85.e18.
17. De Mattia E, Roncato R, Dalle Fratte C, Ecca F, Toffoli G, et al. The use of pharmacogenetics to increase the safety of colorectal cancer patients treated with fluoropyrimidines. Cancer Drug Resist 2019;2:116-30.
18. CPIC® Guideline for Fluoropyrimidines and DPYD November 2018 & January 2020 Updates. Available from: https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/ [Last accessed on 12 Feb 2020].
19. Franca R, Zudeh G, Pagarin S, Rabusin M, Lucafò M, et al. Pharmacogenetics of thiopurines. Cancer Drug Resist 2019;2:256-70.
20. Clinical pharmacogenetics implementation consortium guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update (November 2018). Available from: https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/ [Last accessed on 12 Feb 2020].
21. Abaji R, Krajinovic M. Pharmacogenetics of asparaginase in acute lymphoblastic leukemia. Cancer Drug Resist 2019;2:242-55.
22. Shek D, Read SA, Ahlenstiel G, Piatkov I. Pharmacogenetics of anticancer monoclonal antibodies. Cancer Drug Resist 2019;2:69-81.
23. Murthy P, Muggia F. PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues. Cancer Drug Resist 2019;2:665-79.
24. Kumar S, Kushwaha PP, Gupta S. Emerging targets in cancer drug resistance. Cancer Drug Resist 2019;2:161-77.
25. Belizario JE, Loggulo AF. Insights into breast cancer phenotying through molecular omics approaches and therapy response. Cancer Drug Resist 2019;2:527-38.
26. Ravegnini G, Hrelia P, Angelini S. Somatic pharmacogenomics of gastrointestinal stromal tumor. Cancer Drug Resist 2019;2:107-15.
